NanoVibronix Inc., now ENvue Medical Inc., reports medical-technology developments centered on enteral access, non-invasive therapy and commercialization under the FEED ticker following its completed name and symbol change from NAOV. The company’s ENvue™ Navigation Platform is a minimally invasive electromagnetic navigation system for assisting clinicians with feeding-tube placement in the gastrointestinal tract, with FDA 510(k) clearance for adult use and real-time bedside visualization.
Recurring updates include ENFit syringe launches and distribution, UroShield® reimbursement and market-access developments, patent activity for feeding-tube navigation and visualization, and commercial leadership changes. The company also describes acoustic-based therapeutic technologies, including PainShield® and UroShield®, that use proprietary low-intensity surface acoustic wave technology for pain, bacterial colonization and biofilm-related applications.
NanoVibronix, Inc. announced that its PainShield product will be included in the U.S. Department of Veteran Affairs’ Federal Supply Schedule (FSS) effective May 1, 2024. The five-year contract awarded to distribution partner Delta Medical, will provide a significant opportunity for NanoVibronix to expand the placement of PainShield devices within the VA healthcare network, serving nine million enrolled veterans annually. The contract aims to address the growing need for non-pharmacological pain management solutions, positioning PainShield as a valuable therapeutic option.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.